Page last updated: 2024-12-08
bietaserpine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
bietaserpine: hypotensive agent; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 20054848 |
| CHEMBL ID | 3989595 |
| CHEBI ID | 125518 |
| SCHEMBL ID | 309277 |
| MeSH ID | M0045635 |
Synonyms (44)
| Synonym |
|---|
| D07167 |
| bietaserpine (prop.inn) |
| nsc-369865 |
| 53-18-9 |
| bietaserpina [inn-spanish] |
| bietaserpine |
| methyl 13-(2-(diethylamino)ethyl)-1,2,3,4,4aalpha,5,7,8,13,13bbeta,14,14aalpha-dodecahydro-2alpha,11-dimethoxy-3beta-((3,4,5-trimethoxybenzoyl)oxy)benz(g)indolo(2,3-a)quinolizine-1beta-carboxylate |
| 1-(2-(diethylamino)ethyl)reserpine |
| s 1210 |
| methyl 1-(2-(diethylamino)ethyl)-18beta-hydroxy-11,17alpha-dimethoxy-3beta,20alpha-yohimban-16beta-carboxylate, 3,4,5-trimethoxybenzoate (ester) |
| methyl 13-(2-diethylaminoethyl)-2,11-dimethoxy-3-(3,4,5-trimethoxybenzoyloxy)yohimban-1-carboxylic acid |
| 3-beta,20-alpha-yohimban-16-beta-carboxylic acid, 1-(2-(diethylamino)ethyl)-18-beta-hydroxy-11,17-alpha-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester) |
| einecs 200-165-0 |
| bietaserpinum [inn-latin] |
| methyl 1alpha,2beta,3alpha,4,4aalpha,5,7,8,13,13bbeta,14,14aalpha-dodecahydro-1-(2-diethylaminoethyl)-2,11-dimethoxy-3beta-(3,4,5-trimethoxybenzoyloxy)-benz(g)indole-(2,3-a)quinolizine-1beta-carboxylate |
| n-diaethylaminoaethyl-reserpin [german] |
| l 652 |
| reserpine, 1-(2-(diethylamino)ethyl)- |
| dl 152 |
| nsc 369865 |
| bietaserpine [inn:dcf] |
| (1r,15s,17r,18r,19s,20s)-3-[2-(diethylamino)ethyl]-6,18-dimethoxy-17-[oxo-(3,4,5-trimethoxyphenyl)methoxy]-11,12,14,15,16,17,18,19,20,21-decahydro-1h-yohimban-19-carboxylic acid methyl ester |
| CHEBI:125518 |
| 0p5b94fvd5 , |
| n-diaethylaminoaethyl-reserpin |
| unii-0p5b94fvd5 |
| bietaserpina |
| s-1210 , |
| bietaserpinum |
| BRD-K25210139-001-01-3 |
| SCHEMBL309277 |
| bietaserpine [mi] |
| methyl 13-(2-(diethylamino)ethyl)-1,2,3,4,4a.alpha.,5,7,8,13,13b.beta.,14,14a.alpha.-dodecahydro-2.alpha.,11-dimethoxy-3.beta.-((3,4,5-trimethoxybenzoyl)oxy)benz(g)indolo(2,3-a)quinolizine-1.beta.-carboxylate |
| bietaserpine [who-dd] |
| bietaserpine [mart.] |
| bietaserpine [inn] |
| methyl 1-[2-(diethylamino)ethyl]-18beta-hydroxy-11,17alpha-dimethoxy-3beta,20alpha-yohimban-16beta-carboxylate, 3,4,5-trimethoxybenzoate (ester) |
| dl-152 free base |
| Q4904688 |
| DB13575 |
| CHEMBL3989595 |
| DTXSID301018918 |
| methyl (1r,15s,17r,18r,19s,20s)-3-[2-(diethylamino)ethyl]-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-11,12,14,15,16,17,18,19,20,21-decahydro-1h-yohimban-19-carboxylate |
| AKOS040750798 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " DL-152 was found to be toxic to cells of all the tumor models tested (KHT fibrosarcoma, RIF-1 fibrosarcoma, EMT-6 adenocarcinoma and Lewis lung carcinoma) when the drug was given by intraperitoneal injection to the tumor-bearing mouse and cell survival was measured by excision assay." | ( Factors influencing the toxicity of diethylaminoethylreserpine to tumor cells: studies with four transplantable tumors. Lehnert, S, 1987) | 0.27 |
| " Hypoxic cells were detectable in 10-day-old lung tumors, a time at which the tumors were still resistant to the toxic effects of DL-152." | ( Toxicity of diethylaminoreserpine to a transplantable tumor: the significance of the presence of hypoxic cells. Lehnert, S, 1982) | 0.26 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| yohimban alkaloid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||